MYGN - Mergers and acquisitions

SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 14, 2026 at 5:15 pm PT (8:15 pm ET) in connection with the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference. Select Preliminary Four

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Select Preliminary Fourth Quarter and Full Year 2024 Financial ResultsThe company expects the following: Fourth quarter of 2024 total revenues to be between $209 million and $211 million, an increase of approximately 6% to 7% compared to fourth quarter of 2023. Full year 2024 total revenues to be between $836 million to $838 million, an increase of approximately 11% compared to full year 202

Healthcare providers can easily order Myriad's genetic tests for the more than 250 million patients within Epic's networkPartnership bolsters Myriad's growth plan to scale customer-centric, tech-enabled commercial capabilities with over 600 EHR integrations this year SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company, to integrate Myriad's full line of genetic tests with Epic's expansive network of 600,000 physicians and more than 250 million patients. The integration creates a seamless, end-to-end workflow solu

SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and clarify cancer treatment and risk assessment. The presentations underscore Myriad's commitment to partnering with oncologists and other healthcare partners to support health equity and provide data-driven insights to help guide clinical care and improve outcomes. They follow the recent launch of Precise™ Oncology Solutions, a comprehensive suite of solutions offering germline testing, tumor profi

Precise™ Liquid Biopsy will provide insights on circulating tumor DNA in the blood to help guide cancer treatment decisions SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to its growing oncology portfolio. Compared to standard tissue biopsies, many oncologists prefer liquid biopsy testing to analyze traces of tumor DNA in the blood, providing an often quicker, less invasive alternative for cancer treatment sel

SALT LAKE CITY, March 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the launch of Precise™ Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treatment plans for individual patients. The new suite provides physicians with streamlined testing that combines germline testing, tumor profiling and companion diagnostic options including evaluation for Homologous Recombination Deficiency (HRD), an important cancer repair pathway. Precise Oncology Solutions includes Myriad's new Precise™ Tumor Molecular Profile Test, developed in collaboratio

SALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the U.S. Food and Drug Administration (FDA) has approved Myriad's BRACAnalysis® CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) HER2 negative, high-risk early-stage breast cancer who may benefit from Lynparza®(olaparib). "This most recent regulatory approval confirms the benefits of using biomarkers to help guide care for patients with breast cancer," said Nicole Lambert, chief operating officer, Myriad Genetics. "Data from the OlympiA trial and numerous other clinical studies cont

Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage SALT LAKE CITY, March 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, has been recognized on Fast Company's annual list of the World's Most Innovative Companies for 2022. The list honors businesses that are making the biggest impact in their industries, providing a roadmap for the future of innovation across dynamic sectors of the economy. Myriad placed in the top 10 in the highly competitive Biotech category which recognizes the most innovative scientific laboratories,

SALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished service. A national search for a permanent CSO is underway. Lanchbury will provide consulting and scientific advisory services for Myriad Genetics through the end of the first quarter of 2022. Lanchbury joined Myriad Genetics in September 2002. Most recently, he drove health equity advancements such as Myriad's MyRisk™ Hereditary Cancer Test with RiskScore® for all ancestries. Lanchbury previously led efforts to dev

SALT LAKE CITY, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to Paul J. Diaz, president and CEO, Myriad Genetics. Over a 20-year career at the company, Lambert served in several senior leadership positions, most recently overseeing Myriad's Oncology, Women's Health and International business units as well as genetic testing laboratory operations. As COO, she assumes additional responsibility for accelerating the company's transformation and growth plans, elevating products to t

Highlights: Revenue of $173.1 million increases 12% sequentiallyGAAP earnings per share of ($0.52), adjusted EPS of ($0.06) improves $0.06 sequentiallyTotal test volumes increase 5% sequentially despite typical seasonality, with average revenue per test also increasing relative to the Dec. quarterExpect to close on the sale of the three planned business unit divestitures by the end of 3Q21 for total gross proceeds of approximately $375 millionCompany to host Investor Day on May 4th at 11 am EDT Paul J. Diaz, President and Chief Executive Officer:"Myriad Genetics returned to year-over-year top line growth in the March quarter through improved operational execution amidst the challen

Highlights: Revenue of $154.6 million up 6% sequentially in quarter ended Dec. 31, 2020GAAP Earnings per share (EPS) of ($0.59) and adjusted EPS of ($0.12) Despite COVID-19 headwinds, total test volumes increase 7% sequentially with stable pricingSigned in-network agreement with the majority of Anthem Blue Cross Blue Shield health plans, the second largest commercial payer in the United States, returning all Myriad products to in-network status Paul J. Diaz, President and Chief Executive Officer:“In the midst of the COVID-19 pandemic, we continued to support our patients and healthcare providers with critical genetic insights needed to drive better health outcomes. This quarter we continue